Global Molecular Residual Disease Detection Market Growth (Status and Outlook) 2023-2029

Global Molecular Residual Disease Detection Market Growth (Status and Outlook) 2023-2029

The global Molecular Residual Disease Detection market size is projected to grow from US$ 4578.2 million in 2022 to US$ 13080 million in 2029; it is expected to grow at a CAGR of 16.2% from 2023 to 2029.

United States market for Molecular Residual Disease Detection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Molecular Residual Disease Detection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Molecular Residual Disease Detection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Molecular Residual Disease Detection players cover Adaptive, Guardant Health, Invitae, Cergentis B.V, LexentBio, Natera, BGI, Zhiben Medical and Burning Rock Medicine, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Molecular residual lesions often refer to minimal residual lesions, which refer to a small number of cancer cells that remain in the body after cancer treatment (cancer cells that do not respond to treatment or are drug-resistant).

LPI (LP Information)' newest research report, the “Molecular Residual Disease Detection Industry Forecast” looks at past sales and reviews total world Molecular Residual Disease Detection sales in 2022, providing a comprehensive analysis by region and market sector of projected Molecular Residual Disease Detection sales for 2023 through 2029. With Molecular Residual Disease Detection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Molecular Residual Disease Detection industry.

This Insight Report provides a comprehensive analysis of the global Molecular Residual Disease Detection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Molecular Residual Disease Detection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Molecular Residual Disease Detection market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Molecular Residual Disease Detection and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Molecular Residual Disease Detection.

This report presents a comprehensive overview, market shares, and growth opportunities of Molecular Residual Disease Detection market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Tumor-informed Assays
Tumor-agnostic Assays

Segmentation by application
Prognosis
Adjuvant Treatment Decision-Making
Surveillance for Postoperative Recurrence
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Adaptive
Guardant Health
Invitae
Cergentis B.V
LexentBio
Natera
BGI
Zhiben Medical
Burning Rock Medicine
Huidu Medical
Zhenhe Technology
ExactSciences

Please note: The report will take approximately 2 business days to prepare and deliver.